Amedisys (NASDAQ:AMED) had its price objective boosted by Raymond James from $140.00 to $144.00 in a research report sent to investors on Monday morning, BenzingaRatingsTable reports. The brokerage currently has an outperform rating on the health services provider’s stock.
A number of other research firms have also recently issued reports on AMED. Jefferies Financial Group set a $150.00 price target on Amedisys and gave the stock a buy rating in a report on Monday, July 8th. BidaskClub cut Vertex Pharmaceuticals from a buy rating to a hold rating in a report on Tuesday, July 9th. Barclays set a €77.00 ($89.53) price target on HeidelbergCement and gave the stock a buy rating in a report on Thursday, March 21st. Finally, ValuEngine upgraded Zumiez from a sell rating to a hold rating in a report on Saturday, June 22nd. Seven equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. Amedisys currently has a consensus rating of Buy and an average price target of $131.74.
NASDAQ:AMED opened at $126.07 on Monday. The firm has a market cap of $3.97 billion, a P/E ratio of 31.18, a PEG ratio of 1.54 and a beta of 1.34. Amedisys has a fifty-two week low of $92.08 and a fifty-two week high of $140.91. The firm’s 50 day moving average price is $119.20. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.91 and a quick ratio of 0.91.
Amedisys (NASDAQ:AMED) last posted its quarterly earnings results on Tuesday, April 30th. The health services provider reported $1.11 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.89 by $0.22. The firm had revenue of $467.34 million for the quarter, compared to analysts’ expectations of $460.83 million. Amedisys had a return on equity of 28.25% and a net margin of 7.14%. The company’s revenue for the quarter was up 17.0% compared to the same quarter last year. During the same period in the prior year, the business earned $0.79 EPS. As a group, research analysts expect that Amedisys will post 4.08 EPS for the current fiscal year.
In related news, CFO Scott G. Ginn sold 4,872 shares of the stock in a transaction on Monday, June 10th. The stock was sold at an average price of $118.50, for a total value of $577,332.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider David L. Kemmerly sold 5,000 shares of the stock in a transaction on Monday, May 20th. The stock was sold at an average price of $109.96, for a total value of $549,800.00. The disclosure for this sale can be found here. Over the last quarter, insiders sold 45,028 shares of company stock worth $5,210,707. 2.90% of the stock is owned by company insiders.
Several institutional investors and hedge funds have recently modified their holdings of AMED. Riverbridge Partners LLC bought a new position in shares of Amedisys in the 2nd quarter worth $80,465,000. Norges Bank bought a new position in Amedisys during the 4th quarter valued at $68,342,000. Marshall Wace LLP lifted its stake in Amedisys by 289.2% during the 1st quarter. Marshall Wace LLP now owns 220,503 shares of the health services provider’s stock valued at $27,180,000 after acquiring an additional 163,842 shares in the last quarter. AJO LP lifted its stake in Amedisys by 3,004.4% during the 1st quarter. AJO LP now owns 109,988 shares of the health services provider’s stock valued at $13,557,000 after acquiring an additional 106,445 shares in the last quarter. Finally, Millennium Management LLC lifted its stake in Amedisys by 66.2% during the 4th quarter. Millennium Management LLC now owns 222,513 shares of the health services provider’s stock valued at $26,058,000 after acquiring an additional 88,634 shares in the last quarter. Institutional investors own 86.45% of the company’s stock.
Amedisys Company Profile
Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, social workers, and aides for its patients to complete their important personal tasks.
Recommended Story: What are the Benefits of Index Funds?
Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.